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Abstract
Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and debilitating lung disease with a median survival time 
of 3–5 years. For now, pirfenidone (PIR) and nintedanib (NTB) are the only drugs that can slow down the disease’s progression. 
In Poland, these drugs, although registered for legal use, had not been reimbursed for IPF patients until the end of the year 2016. 
Aim of the study was to assess what was common practice in terms of diagnosis and treatment in the period before antifibrotic 
drugs became available for IPF patients in Poland. 
Material and methods: We performed a survey among participants of two nationwide pulmonological congresses held in 2016. 
Results: One hundred and fifty physicians took part in the study. Only 55% of respondents would reach their final diagnosis in 
collaboration with a radiologist. Just 40% of those sending patients for surgical lung biopsy (SLB) would discuss the case directly 
with a pathologist. 22% would never refer the patient suspected of having IPF for SLB. 85% believed that bronchoalveolar lavage 
(BAL) may be useful for diagnosis. 41% of respiratory professionals would not use any drug for the treatment of IPF patients. 23% 
of physicians would prescribe corticosteroids in high doses (CS), either in monotherapy or in combination with other drugs. Only 
43% of respondents would use antacid drugs in case of symptomatic gastro-oesophageal reflux disease (GERD), and only 11% 
would prescribe these drugs regardless of GERD diagnosis.
Conclusions: The majority of Polish pulmonologists were not supported by radiologists and pathologists in the diagnostic process. 
Treatment standards were unsatisfactory, mostly due to a lacking of reimbursement regulations. Further education is necessary 
to improve management of IPF patients in Poland.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a chro-
nic, progressive and debilitating lung disease, 
with a median survival time of between 3 and 5 
years. According to international guidelines, high 
resolution computed tomography (HRCT) serves 
as the main diagnostic tool. After exclusion of 
known causes of interstitial lung disease (ILD), 
HRCT allows specialists to make a definite diagno-
sis of IPF in around 40–50% of cases. Patients with 
a possible UIP diagnosis based on HRCT evalu-
ation should be referred for lung biopsy [1]. A mul-
tidisciplinary discussion is necessary in order to 
reach a diagnosis in patients with a possible UIP 
pattern or with features inconsistent with UIP [1]. 
It is recommended that the multidisciplinary 
team (MDT) includes specialists in radiology 
and lung pathology as a minimum, alongside 
the expert pulmonologist, with the condition 
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that both specialists are also ILD experts [1]. It 
is implied that the diagnostic process is to be 
completed in an ILD reference centre, following 
the idea that concentration of rare diseases in 
one institution increases diagnostic potential and 
reduces the rate of misdiagnosed cases. 
An update of clinical practice guidelines was 
released in 2015, with new recommendations for 
treatment [2]. According to this document, only 
two drugs are recommended for IPF treatment, 
namely pirfenidone (PIR) and nintedanib (NTB) 
(a weak recommendation has been assigned to 
both drugs) [2]. Corticosteroids (CS) in high 
doses, either in monotherapy or in combination 
with immunosuppressive (IS) drugs, or so called 
triple therapy — CS, azathioprine and N-acetyl-
cysteine (NAC), are strongly contraindicated. 
A strong negative recommendation has been also 
assigned to such treatments as warfarin, ambri-
sentan, imatinib and other drugs, based on the 
results of randomized clinical trials [2]. Based 
on the several suppositions of the potential role 
of gastroesophageal reflux disease (GERD) in IPF 
pathogenesis and progression, it is recommended 
that all patients are treated with antacid therapy 
(AAT), regardless of whether GERD symptoms 
are present or not [2]. Non-pharmacological 
treatments, such as lung transplantation, home 
oxygen supplementation and rehabilitation were 
also assigned positive recommendations.
Today PIR and NTB are available and reim-
bursed in the majority of European countries. 
The European Medicine Agency (EMA) approved 
PIR in 2011 and NTB in 2014 [3]. Although both 
drugs were registered for legal use in Poland, no 
reimbursement regulations were in place until 
the end of 2016. This situation is to change in 
the foreseeable future, as PIR was approved for 
reimbursement in selected IPF patients [4]. Ne-
ither pharmacological nor non-pharmacological 
treatment standards, nor standardized diagnostic 
procedures have been established for Polish IPF 
patients, with regards to the specificity of the 
national health service system, and specific pa-
tients’ needs and expectations. This system, for 
instance, does not favour any high-level referen-
ce medical institutions, which clearly contrasts 
with a recommendation of building-up local ILD 
reference centres. 
In view of the above, the aim of the study was 
to explore what was common clinical practice 
amongst Polish pulmonologists regarding IPF 
diagnosis and treatment, before the change of 
regulations allowing the wider use of antifibrotic 
drugs in IPF patients.
Material and methods
The survey was performed during the Polish 
Respiratory Society (PTChP, Polskie Towarzystwo 
Chorób Płuc) Congress, held in May 2016, and 
during the nationwide symposium organized 
yearly by Warsaw TB and Lung Diseases Research 
Institute (June 2016). These congresses bring 
together pulmonologists and other professionals 
involved in different fields of respiratory medi-
cine. The questionnaires were distributed at the 
entrance to the lecture room during the ILD ses-
sions and were collected at the end of the session. 
In order to prevent double-participation, those 
who completed the questionnaire during the first 
congress were asked to refrain from completing 
the survey during the next symposium. 
The survey consisted of 20 questions, divided 
into three parts: 1. Data describing the physicians 
responding; 2. Diagnostic procedures; and 3. 
Possible treatment options. The questions asked 
in the self-prepared questionnaire are available 
as an on-line supplement.
Data were presented in absolute numbers 
and as percentages. The sampling distribution for 
each answer in relation to different characteristics 
of respondents was checked by Pearson’s Chi-
squared test with Yates continuity correction. 
A  p-value of < 0.05 was considered to be statis-
tically significant.
Results
Description of respondents
One hundred and fifty physicians took part 
in the study. 111 (74%) were above 40 years old. 
127 (85%) declared having a specialization in pul-
monary medicine. 75 physicians (50%) worked 
in non-academic hospitals, 45 (30%) represented 
academic centres or research institutions. Ninety 
(60%) declared being employed, solely or simul-
taneously, in pulmonological out-patient clinics. 
Professional experience in pulmonary medicine 
of 40% of respondents was shorter than 10 years. 
Only 13 respondents (< 8%) admitted not having 
been involved in diagnosis and treatment of ILD. 
From those who were involved in ILD diagnosis 
and treatment, 52% declared having managed 
less than 5 IPF patients per year, whereas only 
12 respondents (< 9%) were involved in the man-
agement of more than 20 IPF patients per year. 
From those who never or only seldom diagnose 
ILD patents, 20 out of 79 (25%) referred patients to 
an institution of a higher reference grade. 58 (73%) 
decided to perform a chest HRCT, and only when 
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Table 1. Characteristics of respondents
Question Answer n (%)#
Age [years] < 30 6 4
30–40 33 22
41–50 51 34
51–60 42 28
> 60 18 12
Specializations* None 5 3
Internal medicine 98 65
Pulmonary medicine 127 85
Allergology 11 7
Family medicine 1 < 1
Other 4 3
Place of work* Hospital — academia/research 75 50
Hospital — non-academic/ 
/non-research
45 30
Pulmonary out-patient 90 60
Family practice 11 7
Other 8 5
Professional 
experience in 
pulmonary me-
dicine (years)
< 5 36 3
6–10 24 16
11–20 37 25
21–30 37 25
31–40 11 7
> 40 5 3
Involved in ILD 
diagnosis and 
treatment?
Yes 88 59
Sometimes 49 33
Never 13 8
If involved — 
number of IPF 
patients per 
year
< 5 71 47
6–20 61 41
21–50 11 7
51–100 1 < 1
> 100 0 0
*the sum of particular items does not equal 100%; #rounded to a whole number 
the suspicion of ILD/IPF was remained did they 
then refer patients to a  higher-grade centre. 
Those employed in academic centres more often 
declared having taken care of > 20 IPF patients 
during last year. The detailed data from this sec-
tion are shown in Table 1.
IPF diagnosis
144 of 150 (93%) participants considered 
HRCT as essential for IPF diagnosis, and the rest 
of the study group would perform this examina-
tion in selected patients only. In the opinion of 
116 respondents (77%), body plethysmography 
and DLCO are indispensable in a clinical work-up 
of IPF patients, and 4 respondents (< 3%) believe 
that these examinations are unnecessary. Almost 
all respondents (148, above 98%) believe that 
a 6-minute walking test should be carried out, at 
least in selected patients suspected of IPF. With 
regards to the use of bronchoalveolar lavage (BAL) 
examination in the diagnosis of IPF, 43 respon-
dents (29%) would perform BAL in all cases, 85 
(56%) in selected patients, and 23 (15%) believe 
that BAL is unnecessary (Fig. 1). 
Almost 23% of respondents never refer pa-
tients for surgical lung biopsy (SLB), 108 (72%) 
would do so for selected patients, and 8 (5%) 
always refer patients for SLB. 6 respondents 
(4%) declared that they make diagnoses without 
consultation with other specialists, 93 (62%) 
discuss the case with other pulmonologists, 
and 82 (55%) respondents discuss it with a ra-
diologist (Fig. 2). When the patient was referred 
for a lung biopsy, only 60 (40%) would discuss 
the results (in face-to-face or a telephone con-
versation) with a  pathologist. Patients were 
referred for surgical lung biopsy more often by 
physicians from academic centres (p = 0.03). 
Physicians from academic centres would also 
discuss the diagnosis directly with a pathologist 
more often when a biopsy is performed (p = 
0.03). Specialists in pulmonary medicine would 
consult with radiologists experienced in ILD di-
agnosis more often (p = 0.01), as would doctors 
from academic centres (p = 0.03). The group of 
physicians aged 51–60 years would discuss the 
IPF diagnosis with other pulmonologists less 
frequently when compared with the other age 
groups (p = 0.02).
Figure 1. The percentage of answers to the question: Do you agree, 
that bronchoalveolar lavage (BAL) is necessary in the differential dia-
gnosis of idiopathic pulmonary fibrosis (IPF)?
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Figure 2. The percentage (x-axis) and number of positive answers (in bars) to the question: Are you assisted by other specialists in the diagnostic 
process? (multiple choice questions, n = 141)
Figure 3. Proportions of answers to the question about pulmonary 
rehabilitation
IPF treatment
Oxygen therapy as an option for IPF patients 
with signs of chronic respiratory failure at rest 
would be recommended by 124 (83%) of physi-
cians, and 25 respondents (17%) would recom-
mend oxygen therapy only for those who present 
hypoxemia with physical effort. Oxygen therapy 
for patients with exercise hypoxemia would be 
recommended more often by specialists in pul-
monary medicine (p = 0.01). Only 31 respondents 
(21%) would refer IPF patients to a rehabilitation 
centre, and 111 (74%) would recommend simple 
forms of physical activity. 7 respondents (< 5%) 
would not try to send a patient for rehabilitation 
due to a lack of rehabilitation units/centres in the 
close vicinity of their institution (Fig. 3). 
More than half of respondents (57%) would 
refer a patient with IPF for lung transplantation 
in case of rapid deterioration, and 2 respondents 
would refer all patients as soon as the IPF diag-
nosis is confirmed. As many as 46 respondents 
(31%) would never refer a patient for lung trans-
plantation because, in their opinion, the access to 
transplantation centres in Poland is too limited. 
6 respondents (4%) do not believe in the effec-
tiveness of this treatment approach, or they do 
not refer their patients to transplantation centres 
due to their own religious or ideological concerns 
(Fig. 4). Doctors from academic centres would 
refer their patients for transplantation more often 
(p = 0.00519).
Still, 13 respondents (9%) declared having 
treated patients with high doses of CS, 16 (11%) 
recommended CS with immunosuppressive 
drugs, and 6 (4%) declared having recommended 
triple therapy (CS+AZA+NAC). Low doses of CS 
were recommended by 28 respondents (19%), 
mostly as symptomatic treatment for cough. 
Steroids in monotherapy or in different combina-
tions were recommended by 43% of respondents. 
Sixty-five (43%) of respondents would use AAT, 
but only 11% would prescribe this therapy ex-
clusively for patients with symptomatic GERD. 
62 (41%) would not use any treatment, mainly 
because effective drugs are not available (Fig. 5). 
Only 17 respondents had ever met a patient 
treated with pirfenidone, and in all cases the 
drug was used as part of a clinical trial. Only two 
respondents had ever met a patient treated with 
nintedanib.
Academic physicians declared more often 
than not that they would recommend some type 
of treatment (p = 0.003).
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Figure 4. Proportions of answers to the question about lung transplantation
Figure 5. The percentage of answers to the question: What drugs do you use in the treatment of idiopathic pulmonary fibrosis (IPF)? (multiple 
choice questions). AAT — antacid therapy; AZA — azathioprine; CS — corticosteroids; GERD —  gastroesophageal reflux disease; IS — immuno-
suppressive drugs; NAC — N-acetylcysteine
Discussion
The idea of performing this survey was 
prompted by the 2013 Advancing IPF Research 
(AIR) survey arranged by Vincent Cottin, whose 
results were published in 2014 [3]. The aim of this 
survey was to assess current approaches to the 
diagnosis and treatment of idiopathic pulmonary 
fibrosis (IPF) by experienced physicians. The au-
thor confirmed a high level of multidisciplinary 
team involvement in both diagnosis and manage-
ment amongst Western European pulmonologists, 
however it also showed that some improvement 
in early diagnosis is needed. There was also 
a follow-up survey showing improvement in the 
adherence to guidelines, mainly with a significant 
decrease of the use of steroids, increase in the pro-
portion of patients treated with pirfenidone, and 
more frequent involvement of multidisciplinary 
teams in the diagnostic process [4].
Our survey was designed to answer the 
question of how Polish physicians (mostly spe-
cialists) deal with the diagnosis and treatment 
of IPF in the specific situation where neither PIR 
nor NTB were available for IPF patients due to 
a lack of reimbursement regulations, regardless 
of positive recommendations from international 
guidelines. In the first part of the survey, we 
confirmed that proper diagnostic tools are used 
for the IPF diagnosis and clinical work-up. The 
percentage of respondents indicating BAL as 
an important diagnostic tool seems to be high. 
Although IPF international guidelines do not 
recommend BAL in the majority of IPF patients, 
placing a high value on the additional risk and 
cost of BAL in patients with IPF and a low value 
on possible improved specificity of diagnosis, this 
trend is in line with many reports pointing out the 
necessity of differentiation between IPF and chro-
nic hypersensitivity pneumonitis (cHP), where 
higher lymphocyte percentage is observed [1, 5]. 
As many as 72% of respondents refer selected 
patients for SLB, which is in line with internatio-
nal recommendations [1], which prompts one to 
consider surgical lung biopsy not only in patients 
with a pattern inconsistent with UIP but also in 
those with a possible UIP pattern (when there is 
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no honeycombing, but all other criteria for UIP 
are met).
The need for a multidisciplinary team, con-
sisting of a pulmonologist, a radiologist and a pa-
thologist is emphasized in the guidelines [1]. All 
these specialists should have vast experience in 
the field of ILD. In our survey only about 55% of 
respondents had the option of consulting the IPF 
diagnosis during discussion with an experienced 
radiologist, and only 40% of those who refer their 
patients for lung biopsy (either always or in selec-
ted cases) discuss the results with a pathologist. 
These results show the necessity of building 
up the real multidisciplinary teams in Polish 
pulmonary centres, which aspire to achieve the 
reference standard. This process may take a long 
time, as it usually takes a few years to gain enough 
experience in this area.
Given that the survey was performed before 
antifibrotic drugs were available for Polish IPF 
patients, it is obvious that Polish pulmonologists 
could not comply with the recommendation for 
the use of antifibrotic drugs in the treatment of IPF. 
In total, 24% of respondents still used high 
doses of steroids or other immunosuppressive 
agents, which was clearly against guidelines. 
This percentage was even higher in the first AIR 
survey, reaching 49 % in total [3]. Increased 
availability of antifibrotic drugs in France and 
other Western European countries has reduced 
the use of other therapies in follow-up to 7% [4]. 
AAT is recommended for all patients with IPF, 
regardless of whether the disease is symptomatic 
or not. This recommendation was sustained in 
a document updated in 2015 [2]. Although the 
role of recurrent microaspirations due to GERD in 
the pathogenesis of IPF and its progression is not 
fully explained, there are strong data supporting 
this hypothesis [6, 7]. Therefore, due to the vast 
availability of these drugs, low costs and possible 
protection against the progression of lung fibrosis, 
these drugs should be used more widely. In our 
survey only 43% of physicians prescribed AAT, 
and only 11% did so in patients without gastro-
intestinal symptoms. 
Where non-pharmacological treatment is 
concerned, home oxygen therapy, pulmonary 
rehabilitation and lung transplantation are re-
commended for IPF patients who meet specific 
indications [1, 2]. Oxygen in those with signi-
ficant resting hypoxemia is indicated (strong 
recommendation, very low-quality evidence), 
but specific criteria in terms of PaO2 threshold or 
duration of supplementation (hrs per day) have 
not been established in IPF. In practice, general 
criteria for home oxygen therapy are used, which 
are elaborated based on the population of COPD 
patients. Although there are no clear data sho-
wing that oxygen supplementation in IPF patients 
improves survival rates, it may improve exercise 
tolerance [8]. There is an assumption that exercise 
tolerance and quality of life may be improved by 
the use of mobile oxygen sources during exercise, 
especially in those with significant exertional 
hypoxemia, but strong evidence supporting this 
opinion is lacking. Nevertheless, although the 
majority of respondents would recommend oxy-
gen supplementation in IPF patients with resting 
hypoxemia, only 83% of those patients with do-
ubtless indications for oxygen therapy would be 
prescribed domiciliary oxygen.
Pulmonary rehabilitation is also recommended 
in IPF patients by international guidelines (weak 
recommendation, low-quality evidence) [1, 2]. 
There are a few studies showing improvement in wal-
king distance, symptoms and quality of life [9, 10]. 
Pulmonary rehabilitation clearly exceeds “simple 
forms of physical activity” and involves aerobic 
conditioning, strength and flexibility training, 
educational lectures, nutritional interventions, 
and psychosocial support. IPF warrants easier 
access to dedicated rehabilitation centres, but this 
condition is difficult to meet due to a lacking of 
such centres (the authors are aware of a maximum 
of 3–5) in Poland. The results of our survey reflect 
this poor state of Polish rehabilitation, as only 21% 
of respondents would send the patient to a rehabi-
litation centre and the majority would recommend 
simple forms of physical activity. 
It is of note that lung transplantation is 
recommended by international experts for ap-
propriate patients [1]. Referral for transplantation 
is encouraged in appropriate patients at the time 
of diagnosis, and detailed evaluation for lung 
transplantation should occur in a timely manner 
at the first sign of any deterioration [1], for instan-
ce in those with > 10% decrease in FVC in the last 
6 months or after experiencing acute exacerba-
tion. In our study as many as 31% of respondents 
would not refer patients for lung transplantation 
due to poor access to transplantation centres. 
This problem requires further detailed analysis. 
In conclusion, the majority of Polish phy-
sicians who are involved in the diagnosis and 
treatment of IPF patients are aware of the most 
important international guidelines’ recommen-
dations. The survey shows that the involvement 
of other specialists in the process of differential 
diagnosis is insufficient. Treatment standards 
were not met, mainly due to a lack of access to 
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antifibrotic therapies. Further education is indica-
ted to improve treatment standards. The authors 
would like to follow-up on the situation in this 
field by the use of a repeated survey in the future. 
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